News

The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate,…

Homes and landmarks across the U.S. and other countries will once again light up in red throughout March for Amyloidosis Awareness Month as the…

Signs of more advanced heart disease and the presence of nerve involvement are associated with a higher risk of worse outcomes, including heart failure, hospitalization…

An easily accessible diagnostic test called pain-related evoked potentials with concentric electrodes (PrEP-CE) may help detect the onset of hereditary transthyretin amyloidosis with polyneuropathy…

Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) across…

Overactivation of Rac1, a protein that regulates components of a cell’s skeleton, may drive early nerve damage in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN),…

Blood levels of signaling molecules that promote tissue scarring, or fibrosis, are elevated in people with transthyretin amyloid cardiomyopathy (ATTR-CM), and higher levels of…

Minimally invasive skin biopsies may be used to diagnose transthyretin amyloidosis and guide treatment in people with the rare progressive disease, according to the findings…

People with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer when the disease is diagnosed and treated earlier, with treatment benefits being much smaller in older…

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 3 clinical trial testing the investigational gene-editing therapy, nexiguran ziclumeran…